Past exposure to neuroleptics is associated with the risk of developing Parkinson's disease
J. Friedman
DOI: https://doi.org/10.1136/eb-2012-101129
2012-12-14
Evidence-Based Mental Health
Abstract:ED FROM Foubert-Samier A, Helmer C, Perez F, et al. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology 2012;79:1615–21 Correspondence to: Dr Alexandra Fouber-Samier, Institut de Santé Publique d’Epidemiologie et de Développement, Université Victor Segalen Bordeaux 2, 146 Rue Lèo Saignat, 33076 Bordeaux, France; alexandra.foubert@isped.u-bordeaux2.fr Sources of funding ISPEN France, NOVARTIS Pharma France, and the Caisse Nationale de Solidarité et d’Autonomie. ▸ Additional material is published online only. To view this file please visit the journal online (http://dx.doi.org/10.1136/eb-2012-101129). OM M EN TRY Large numbers of risk factors have been reported for idiopathic Parkinson’s disease (PD). Most have been identified in retrospective case– control studies. Some have emerged from large-scale prospective studies aimed at multiple health outcomes. Dopamine receptor blocking drugs (DRBD) have not raised a concern until now. Long-term use of DRBD has not been found to cause neuronal damage. The dopaminergic system in the brain is, however, subject to long-term, probably permanent changes induced by exposure to DRBD, as evidenced by tardive dyskinesia. The hypothesis that neuroleptics contribute to PD risk rather than accelerated PD identification, therefore, has a plausible foundation. There is, however, long-term experience with DRBD use in schizophrenics and reports on their developing PD are rare. While this certainly may be due to a number of biases and confounders, the lack of a recognised problem provides a skeptical backdrop to this study. This prospective study was ambitious, involving patient evaluations over 15 years by trained staff. No large, complicated, multiyear undertaking such as this could be perfect. The protocol is subject to different critiques by different critics. The first problem represents the sample, which was drawn from electoral rolls. The second is the recruitment rate of 60%, of whom 41% were men. More importantly, parkinsonism screening was made initially via questionnaire, buttressed by trained personnel who were psychologists, not neurologists. The diagnosis of PD was made by movement specialists based on chart review, not clinical examination. The positive association found at 3 months off DRBD became non-significant when the withdrawal time between drug use and identification of PD was set at 2 years, possibly due to small numbers. Although drug-induced parkinsonism (DIP) usually resolves within a few months of drug discontinuation, it may last many years, and after several years, some progression of parkinsonism may occur due to aging itself, confounding a diagnosis of PD. While there are many reasons for neuroleptics to be avoided in the elderly, the prospect of their increasing the risk of developing idiopathic PD is not clearly one of them. Competing interests None. Joseph Harold Friedman Movement Disorders Program, Butler Hospital, Providence, Rhode Island, USA and Department of Neurology, Alpert Medical School of Brown University, Providence, Rhode Island, USA EBMH February 2013 Vol 16 No 1 27 Aetiology